Stemirna Therapeutics

About Stemirna Therapeutics

Stemirna Therapeutics, established in Shanghai in 2016 by founder and CEO Dr. Hangwen Li, is a biopharmaceutical company that specializes in messenger RNA (mRNA) technology. The founding team was composed of doctors who returned to China after working at the University of Texas MD Anderson Cancer Center. Initially, the company's research and development efforts were directed toward creating personalized oncology vaccines.

The company's core business revolves around its proprietary technologies, including an mRNA synthesis platform and a lipopolyplex (LPP) nano-delivery platform, to develop vaccines and therapeutics. These platforms are applied across various therapeutic areas such as immuno-oncology and infectious diseases. A key product developed was a COVID-19 mRNA vaccine, which received emergency use authorization in Laos. The company's pipeline has also included candidates for influenza, acute myeloid leukemia (AML), and various cancers. To support its ambitions, Stemirna established significant in-house manufacturing capabilities, with a stated capacity of 400 million vaccine doses annually across two facilities in Shanghai.

Riding the wave of interest in mRNA technology during the COVID-19 pandemic, Stemirna secured substantial funding from prominent investors. In June 2021, it raised nearly $200 million in a financing round led by investors like Sequoia Capital China and Wuxi Apptec. This capital was intended to accelerate clinical trials and build out production facilities. However, the company faced challenges as the pandemic subsided. Its COVID-19 vaccine was not approved for the market in China, and demand plummeted before its manufacturing facilities could generate revenue. This led to significant financial difficulties, including numerous lawsuits over contract disputes, defaults on payments, and a halt in production at its vaccine factory. In response to these pressures, Stemirna announced a strategic pivot in late 2023. The company now aims to leverage its expertise and infrastructure to operate as a contract development and manufacturing organization (CDMO) and a contract research organization (CRO) for global partners in the pharmaceutical industry.